Login to Your Account



Medivation showcases PARP inhibitor's potential, baiting bidders

By Michael Fitzhugh
Staff Writer

Thursday, July 7, 2016

Another "multibillion-dollar opportunity" is how Medivation Inc. CEO David Hung framed talazoparib, the company's late-stage PARP inhibitor, in an investor call late Wednesday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription